<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00455884</url>
  </required_header>
  <id_info>
    <org_study_id>2-79-58035-006</org_study_id>
    <nct_id>NCT00455884</nct_id>
  </id_info>
  <brief_title>A Post Marketing Surveillance Study for NutropinAq速 in Adults With Growth Hormone Deficiency</brief_title>
  <official_title>International Cooperative Metabolic Study (iNCMS) of NutropinAq速 [Somatropin (rDNA Origin) Injection] Replacement Therapy in Adults With Growth Hormone Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter, open-label, observational, post marketing surveillance program
      to collect information on the use of NutropinAq速 in adults suffering from Growth Hormone
      Deficiency in Germany, Italy, and United Kingdom
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of serious adverse events</measure>
    <time_frame>when reported</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of targeted adverse events, including adrenal insufficiency, arthritis, carpal tunnel syndrome, intracranial hypertension, new onset and recurrence of leukemia &amp; tumor, pancreatitis, peripheral edema requiring medical intervention and death</measure>
    <time_frame>when reported</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of intercurrent cardiovascular events</measure>
    <time_frame>when reported</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of fractures</measure>
    <time_frame>when reported</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">546</enrollment>
  <condition>Growth Hormone Disorders</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients treated with NutropinAq in the specialised adult endocrinology centres in
        Germany, Italy, and UK.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Growth Hormone Deficiency

          -  Patients treated with NutropinAq速

          -  Patients having completed growth (fused epiphyses)

        Exclusion Criteria:

          -  Active neoplasia

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascale Dutailly, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ipsen Central Contact</name>
      <address>
        <city>Slough</city>
        <state>Berkshire</state>
        <zip>SL1 3XE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2007</study_first_submitted>
  <study_first_submitted_qc>April 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2007</study_first_posted>
  <last_update_submitted>April 3, 2012</last_update_submitted>
  <last_update_submitted_qc>April 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dwarfism, Pituitary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

